Head to Head Contrast: CorMedix (NASDAQ:CRMD) and Abbott Laboratories (NYSE:ABT)

CorMedix (NASDAQ:CRMD) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares CorMedix and Abbott Laboratories”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$82.55 million	10.07	-$46.34 million	$0.22	55.73
Abbott Laboratories	$42.34 billion	5.40	$13.40 billion	$7.71	17.05

Abbott Laboratories has higher revenue and earnings than CorMedix. Abbott Laboratories is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for CorMedix and Abbott Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0	0	6	1	3.14
Abbott Laboratories	0	4	14	1	2.84

CorMedix presently has a consensus target price of $15.00, indicating a potential upside of 22.35%. Abbott Laboratories has a consensus target price of $142.59, indicating a potential upside of 8.46%. Given CorMedix’s stronger consensus rating and higher probable upside, analysts plainly believe CorMedix is more favorable than Abbott Laboratories.

Institutional and Insider Ownership

34.2% of CorMedix shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 5.2% of CorMedix shares are held by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

CorMedix has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Profitability

This table compares CorMedix and Abbott Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CorMedix	N/A	-79.21%	-64.68%
Abbott Laboratories	31.95%	20.74%	11.19%

Summary

Abbott Laboratories beats CorMedix on 9 of the 14 factors compared between the two stocks.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.